Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

Nicola Potere^{1

2}, Marcello Di Nisio^{3

4}, Donatella Cibelli⁵, Rosa Scurti⁶, Antonella Frattari⁷, Ettore Porreca¹, Antonio Abbate², Giustino Parruti⁸

Affiliations

¹ Department of Medical, Oral and Biotechnological Sciences, Università degli Studi Gabriele d'Annunzio, Chieti, Italy.
² VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
³ Department of Medicine and Ageing Sciences, Università degli Studi Gabriele d'Annunzio, Chieti-Pescara, Italy.
⁴ Department of Vascular Medicine, Amsterdam UMC Location AMC, Amsterdam, North Holland, Netherlands.
⁵ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
⁶ Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy.
⁷ Intensive Care Unit, Pescara General Hospital, Pescara, Italy.
⁸ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy parrutig@gmail.com.

Comment

Nicola Potere et al. Ann Rheum Dis. 2022 Nov.

. 2022 Nov;81(11):e215.

doi: 10.1136/annrheumdis-2020-218626. Epub 2020 Jul 31.

Nicola Potere^{1

2}, Marcello Di Nisio^{3

4}, Donatella Cibelli⁵, Rosa Scurti⁶, Antonella Frattari⁷, Ettore Porreca¹, Antonio Abbate², Giustino Parruti⁸

¹ Department of Medical, Oral and Biotechnological Sciences, Università degli Studi Gabriele d'Annunzio, Chieti, Italy.
² VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
³ Department of Medicine and Ageing Sciences, Università degli Studi Gabriele d'Annunzio, Chieti-Pescara, Italy.
⁴ Department of Vascular Medicine, Amsterdam UMC Location AMC, Amsterdam, North Holland, Netherlands.
⁵ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
⁶ Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy.
⁷ Intensive Care Unit, Pescara General Hospital, Pescara, Italy.
⁸ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy parrutig@gmail.com.

No abstract available

Keywords: anti-inflammatory agents; biological therapy; cytokines; inflammation; non-steroidal.

Conflict of interest statement

Competing interests: None declared.

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9. Ann Rheum Dis. 2021. PMID: 32647027 No abstract available.
Rational use of tocilizumab in COVID-19.
Jain S, Sharma SK. Jain S, et al. Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737106 No abstract available.